### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the

Instru	ction 1(b).			111	vesi	ment C	omp	any Act	01	1940							
(Print or Ty	pe Response	s)															
1. Name and Address of Reporting Person Trombly Amy Moss  (Last) (First) (Middle)  C/O SONOMA PHARMACEUTICALS, INC., 1129 NORTH MCDOWELL BLVD.  (Street)				Sonoma Pharmaceuticals, Inc. [SNOA]  3. Date of Earliest Transaction (Month/Day/Year) 12/31/2019								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner					
												X Officer (give title below) Other (specify below)  Chief Executive Officer  6. Individual or Joint/Group Filing(Check Applicable Line)  X Form filed by One Reporting Person  Form filed by More than One Reporting Person					
																	PETALUMA, CA 94954 (City) (State) (Zip)
1.Title of Security (Instr. 3)  2. Transaction Date (Month/Day/Yea				2A. Deemed Execution Date, any (Month/Day/Yea				nsaction	4. S (A)	. Securities Acquired A) or Disposed of (D Instr. 3, 4 and 5)		5. Amount of Securities Owned Following Repor Transaction(s) (Instr. 3 and 4)		eneficially d	6. Ownership Form: Direct (D) or Indirect	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code V Amount (D) Price					(I) (Instr. 4)	(						
		3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if	(e.g., puts, calls  4. 5. Transaction of Code Sc (Instr. 8) A or of		5. Numb of Deriv Securitie Acquire or Dispo of (D) (Instr. 3.	Ils, warrants, of 5. Number of Derivative lasecurities (Acquired (A) or Disposed of (D)  Instr. 3, 4,		displays a currently wired, Disposed of, or Bene- options, convertible securi 6. Date Exercisable and Expiration Date (Month/Day/Year)		ficially O	Owned and Amount rlying es	nt 8. Price of	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(	Ownersh Form of Derivati Security Direct (I or Indire	Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisab		Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	(Instr. 4	)	
Stock option (right to buy)	\$ 4.36	12/31/2019		A		13,491		(1)		12/31/2019	Comme	113.491	<u>(2)</u>	13,491	D		
Stock option (right to buy)	\$ 4.55	01/02/2020		A		2,380		(3)	(	01/02/2021	Comm	2.380	<u>(2)</u>	15,871	D		
Repor	ting O	wners															

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Trombly Amy Moss C/O SONOMA PHARMACEUTICALS, INC. 1129 NORTH MCDOWELL BLVD. PETALUMA, CA 94954			Chief Executive Officer				

## **Signatures**

/s/ Amy Trombly	01/03/2020
**Signature of Reporting Person	Date

# **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The options vest in two equal tranches: the first half vest on 7/1/2020 and the remaining half vest on 12/31/2020.
- (2) The options were awarded and granted to Ms. Trombly for services performed.
- $\textbf{(3)} \ \ \text{The options vest in two equal tranches: the first half vest on } \ 7/2/2020 \ \ \text{and the remaining half vest on } \ 1/2/2021.$

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.